Intersect ENT Snags FDA Approval for In-Office Sinus Implant Treatment

December 12, 2017

The FDA approved the SINUVA Sinus Implant, manufactured by Intersect ENT.

SINUVA is designed using bioabsorbale polymers to treat recurrent nasal polyps in patients who have previously undergone sinus surgery.

It can be inserted by physicians trained in otolaryngology during a routine office visit. It works by expanding the sinus cavity to deliver an anti-inflammatory steroid to the polyp disease site.

The implant softens and polyps decrease over time so patients have the ability to remove it by simply sneezing or blowing their nose after 90 days or earlier.

View today's stories